Association of Left Atrial Volume Changes After Cardioversion and Recurrence of Atrial Fibrillation After Radiofrequency Ablation in Patients With Persistent Atrial Fibrillation

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

Electrical/pharmacological cardioversion improves structural remodeling of left atrium. We hypothesize that persistent atrial fibrillation (AF) patients with more significant left atrial size reduction after cardioversion have lower AF recurrence rates following radiofrequency ablation. The aim is to evaluate the relationship between changes in left atrial size 3 to 6 months after cardioversion and the recurrence rate of atrial fibrillation following radiofrequency ablation.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients with estabolished diagnosis of Persistent Atrial Fibrillation during past 6 mnths.

• LAD brfore entering the two cohorts is more than 40mm, and less than 50mm.

• Pharmacological or electrical cardioversion has be performed successfully.

• At least two echocardiograms were performed before and 3-6 months after cardioversion., and confirm the status of LAD (Reversal, unchange, enlargment).

• Patients have given informed consent.

Locations
Other Locations
China
The Second Affiliated Hospital of Chongqing Medical University
RECRUITING
Chongqing
Contact Information
Primary
Yuehui Yin, MD
yinyh@hospital.cqmu.edu.cn; yinyh63@163.com
+8613508335502
Backup
Fang Qin, MD
qinfangheart@126.com
+8617308351199
Time Frame
Start Date: 2019-07-01
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 100
Treatments
Reversible Group
Left atrial volume (LAV) decreased by 15% 3 to 6 months after electrical/pharmacological cardioversion compared to baseline. Consequently, patients in the group will receive pulmonary vein isolation only.
Irreversible Group
Left atrial volume (LAV) decreased by less than 15% 3 to 6 months after electrical/pharmacological cardioversion compared to baseline. Patients in the group will receive pulmonary vein isolation only.
Related Therapeutic Areas
Sponsors
Leads: The Second Affiliated Hospital of Chongqing Medical University

This content was sourced from clinicaltrials.gov

Similar Clinical Trials